Iqvia Holdings is a global leader in advancing healthcare by providing data analytics, technology, and consulting services to the pharmaceutical and life sciences industries. The company specializes in helping organizations improve their clinical trials, optimize research and development processes, and enhance patient engagement. By leveraging its extensive data assets and innovative technology platforms, Iqvia aids clients in making informed decisions that drive efficiency and effectiveness in bringing new therapies to market. Read More
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how drug development inputs & services stocks fared in Q2, starting with IQVIA (NYSE:IQV).
IQVIA (NYSE: IQV) and Veeva Systems (NYSE: VEEV) today announced global clinical and commercial partnerships and the complete resolution of all pending legal disputes. Under the terms of the long-term agreement, customers can use software, data, technology, and service offerings from Veeva and IQVIA together in a simple and efficient way.
A company that generates cash isn’t automatically a winner.
Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.
A number of stocks jumped in the afternoon session after positive inflation data fueled hopes for an interest rate cut by the Federal Reserve. The latest Consumer Price Index (CPI) report showed inflation rose by a modest 0.2% in July and 2.7% over the last year. This cooler-than-expected data prompted a significant market rally, with the S&P 500, Dow, and Nasdaq all climbing as investors grew more optimistic. The prevailing view is that easing inflation gives the central bank room to lower interest rates. Lower rates typically reduce borrowing costs for businesses and make stocks more attractive relative to bonds, contributing to widespread gains across sectors like healthcare.
Large-cap stocks usually command their industries because they have the scale to drive market trends.
The flip side though is that their sheer size can limit growth as expanding further becomes an increasingly challenging task.
Shares of clinical research company IQVIA (NYSE: IQV)
jumped 3% in the afternoon session on continued positive momentum after the company reported better-than-expected second-quarter earnings and received several price target increases from Wall Street analysts.
Clinical research company IQVIA (NYSE: IQV) announced better-than-expected revenue in Q2 CY2025, with sales up 5.3% year on year to $4.02 billion. The company’s full-year revenue guidance of $16.2 billion at the midpoint came in 0.8% above analysts’ estimates. Its non-GAAP profit of $2.81 per share was 1.4% above analysts’ consensus estimates.
Shares of clinical research company IQVIA (NYSE: IQV)
jumped 15.9% in the morning session after the company reported second-quarter financial results that beat Wall Street expectations and raised its full-year profit guidance.
Let's delve into the developments on the US markets in the middle of the day on Tuesday. Below, you'll find the top gainers and losers within the S&P500 index during today's session.
Clinical research company IQVIA (NYSE: IQV) reported Q2 CY2025 results topping the market’s revenue expectations, with sales up 5.3% year on year to $4.02 billion. The company’s full-year revenue guidance of $16.2 billion at the midpoint came in 0.8% above analysts’ estimates. Its non-GAAP profit of $2.81 per share was 1.4% above analysts’ consensus estimates.
Before the opening bell on Tuesday, let's take a glimpse of the US markets and explore the S&P500 top gainers and losers in today's pre-market session.
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today reported financial results for the quarter ended June 30, 2025.
